Tirzepatide

Dual incretin agonist acting on both GIP and GLP-1 receptors for enhanced glucose control and weight loss

• ·Metabolic Alcohol-associated Liver Disease
• ·Alcohol Use Disorder
• ·Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
• ·FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
• ·Obesity and Obesity-related Medical Conditions

No curated interaction pairs are recorded for Tirzepatide. This is not a statement that none exist — check a full interaction reference before combining.

• Nausea
• Diarrhea
• Decreased appetite
• Vomiting
• Constipation

Half-life

5 days

Protein binding

99%

Not recorded for Tirzepatide. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.